ED
Etzer Darout Barclays Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
62
Avg Return
Past Year
Past Year
6.6%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Positive
81.8%
Neutral
10.6%
Negative
7.6%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Mega Cap
Over $200B
Large Cap
$10B to $200B
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Healthcare
Healthcare
Biotechnology
Drug Manufacturers - General
| Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Buy
Maintained
| $13 |
214%
upside
| 2 | +36% |
0
%
| 2 Sep ‘25 3 months ago |
|
|
|
Buy
Maintained
| $24 |
116%
upside
| 1 | +169% |
0
%
| 15 Apr ‘25 7 months ago |
|
|
|
Outperform
Maintained
| $143 |
48%
upside
| 1 | -8.2% |
0
%
| 11 Mar ‘25 8 months ago |
|
|
|
Market Perform
Downgraded
| $3 |
16%
downside
| 3 | -61% |
0
%
| 11 Feb ‘25 9 months ago |
|
|
|
Market Perform
Downgraded
| $2 | – | 2 | -34% |
0
%
| 10 Jan ‘25 10 months ago |
|
|
|
Outperform
Initiated
| $50 | – | 1 | +100% |
0
%
| 6 Dec ‘24 1 year ago |
|
|
|
Outperform
Initiated
| $35 |
108%
upside
| 1 | -16% |
0
%
| 6 Dec ‘24 1 year ago |
|
|
|
Outperform
Initiated
| $63 |
3,718%
upside
| 1 | -92% |
0
%
| 6 Dec ‘24 1 year ago |
|